Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a large decline in short interest in September. As of September 15th, there was short interest totaling 21,975 shares, a decline of 44.1% from the August 31st total of 39,331 shares. Based on an average daily volume of 27,758 shares, the short-interest ratio is currently 0.8 days. Approximately 3.5% of the shares of the stock are sold short.

Insider Buying and Selling at Shuttle Pharmaceuticals

In other news, major shareholder Financial Lp Hrt sold 18,531 shares of the stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $3.52, for a total value of $65,229.12. Following the completion of the transaction, the insider owned 52,274 shares in the company, valued at $184,004.48. This trade represents a 26.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have acquired 16,848 shares of company stock worth $58,005 and have sold 38,133 shares worth $132,128. 0.36% of the stock is currently owned by company insiders.

Analyst Ratings Changes

SHPH has been the subject of a number of research analyst reports. Weiss Ratings cut shares of Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Shuttle Pharmaceuticals Trading Up 3.1%

Shares of NASDAQ SHPH traded up $0.12 during midday trading on Wednesday, reaching $4.04. 31,235 shares of the stock were exchanged, compared to its average volume of 847,586. The stock has a 50 day moving average price of $3.64 and a 200-day moving average price of $5.37. The company has a market capitalization of $2.57 million, a P/E ratio of -0.22 and a beta of 0.21. Shuttle Pharmaceuticals has a 52-week low of $2.58 and a 52-week high of $55.90.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc is a clinical-stage specialty pharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer patients. The company’s research centers on radiosensitizers, which are intended to make tumor cells more sensitive to radiation while helping preserve surrounding healthy tissue.

Shuttle’s lead product candidate is ropidoxuridine, an orally administered investigational therapy being developed for use in combination with radiation therapy.